Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era

Bibliography

• Rodríguez A, Santaera O, Larribau M, Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis. Am J Cardiol 1993;71:1391-5
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Palacios I, Fernández M, Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995;76:1131-4
   PubMed Web of Science ®Google Scholar
• Mintz G, Popma J, Pichard A, Arterial remodeling after coronay angioplasty. A serial intravascular ultrasound study. Circulation 1996;94:35-44
   PubMed Web of Science ®Google Scholar
• Califf RM, Fortin DF, Frid DJ, Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol 1991;66:3-6
   Google Scholar
• Dimas AP, Grigera F, Arora R, Repeat coronary angioplasty as treatment of restenosis. J Am Coll Cardiol 1992;19:1310-4
   PubMed Web of Science ®Google Scholar
• Serruys PW, De Jaegere P, Kiemeney F, A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS, A randomized comparison of coronary-stent placement and balloon angioplasty in treatment of coronary artery disease. N Engl J Med 1994;331:496-501
   PubMed Web of Science ®Google Scholar
• Gallo R, Padurean A, Jayaraman T, Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99(16):2164-70
   PubMed Web of Science ®Google Scholar
• Waksman R, Ajani AE, White RL, Five years follow up after intracoronary gamma radiation therapy for in stent restenosis. Circulation 2000;109:340-7
   Web of Science ®Google Scholar
• Doyle B, Rihal CS, O'Sullivan CJ, Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116(21):2391-8
   PubMed Web of Science ®Google Scholar
• Popma JJ, Decesare NB, Ellis SG, Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy. Circulation 1991;84:644-53
   PubMed Web of Science ®Google Scholar
• Topol EJ, Leya F, Pinkerton CA, A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993;329:221-7
   PubMed Web of Science ®Google Scholar
• Stankovic G, Colombo A, Bersin R, Comparison of directional coronary atherectomy and stenting versus stenting alone for the treatment of de novo and restenotic coronary artery narrowing. Am J Cardiol 2004;93(8):953-8
   PubMed Web of Science ®Google Scholar
• Al Suwaidi J, Holmes DR, Salam AM, Impact of coronary artery stents on mortality and nonfatal myocardial infaction: meta-analysis of randomized trials comparing strategy of routine stenting with that of balloon angioplasty. Am Heart J 2004;147:815-22
   PubMed Web of Science ®Google Scholar
• Daemen J, Boersma E, Flather M, Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. Circulation 2008;118(11):1146-54
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Boothroyd DB, Bravata DM, Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009;373(9670):1190-7
   PubMed Web of Science ®Google Scholar
• Sousa JE, Costa MA, Abizaid AC, Sustained suppression of neointimal proliferation by sirolimus-eluting stents. one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, A randomized comparison of sirolimus-eluting stent with a standard stent for coronary revascularitation. N Eng J Med 2002;346:1773-80
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23
   PubMed Web of Science ®Google Scholar
• Grube E, Silber S, Hauptmann KE, TAXUS I. Six- and twelve month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A, Randomized study to assess the effectiveness of slow- and moderate-release polymer based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94
   PubMed Web of Science ®Google Scholar
• Spaulding C, Daemen J, Boersma E, A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Eng J Med 2007;356:989-97
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Joner M, Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008;118:1138-45
   PubMed Web of Science ®Google Scholar
• Vorpahl M, Nakazawa G, Kolodgie F, Virmani R. Stent related death rates are higher in drug eluting stents than bare metal stents: an autopsy study. Euro PCR 2009;1:abstract -E 118
   Google Scholar
• Virmani R, Guagliumi G, Farb A, Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we cautious? Circulation 2004;109:701-5
   PubMed Web of Science ®Google Scholar
• Togni M, Windecker S, Cocchia R, Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-6
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakasawa G, Pathological correlates of late drug eluting stents thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41
   PubMed Web of Science ®Google Scholar
• Hong MK, Mintz GS, Lee CW, Late stent malapposition after DES implantation: an intravascular ultrasound analysis with long term follow up. Circulation 2006;113:414-19
   PubMed Web of Science ®Google Scholar
• Kotani J, Awata M, Nanto S, Incomplete neointimal coverage of sirolimus-eluting stents angioscopic findings. J Am Coll Cardiol 2006;47:2108-11
   PubMed Web of Science ®Google Scholar
• Meier P, Zbinden R, Togni M, Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 2007;49:15-20
   PubMed Web of Science ®Google Scholar
• MacFadden EP, Stabile E, Regar E, Late stent trombosis in drug-eluting coronary stent after discontinuation of antiplatelet therapy. Lancet 2004;364:1419-21
   Google Scholar
• Rodríguez AE, Mieres J, Fernández-Pereira C, Coronary stent trombosis in drug-eluting stent era: Insights from ERACI III trial. J Am Coll Cardiol 2006;47:205-7
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Rodriguez-Granillo G, Palacios I. Late stent thrombosis the damocles sword of drug eluting stents. EuroIntervention 2007;2:512-17
   PubMedGoogle Scholar
• Versaci F, Gaspardone A, Fabrizio E, Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-42
   PubMed Web of Science ®Google Scholar
• Ribichini F, Tomai F, Ferrero V, Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study. EuroIntervention 2005;2:173-80
   Google Scholar
• Ferrero V, Tomai F, Versaci F, Long term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C- reactive protein levels. EuroIntervention 2009;5:250-4
   PubMedGoogle Scholar
• Rodriguez AE, Alemparte MR, Vigo CF, Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: argentina single-center study (ORAR Trial). J Invasive Cardiol 2003;15(10):581-4
   PubMedGoogle Scholar
• Rodriguez AE, Granada JF, Rodriguez- Alemparte M, Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the prospective randomized oral rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006;47(8):1522-9
   PubMed Web of Science ®Google Scholar
• Hausleiter J, Kastrati A, Mehilli J, Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110(7):790-5
   PubMed Web of Science ®Google Scholar
• Waksman R, Ajani AE, Pichard AD, Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004;44(7):1386-92
   PubMed Web of Science ®Google Scholar
• Poon M, Marx SO, Gallo R, Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98(10):2277-83
   PubMed Web of Science ®Google Scholar
• Farb A, Jhon M, Acampado E, Oral Everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-84
   PubMed Web of Science ®Google Scholar
• Dong-Woon K, Jin-Sook K, Young-Gyu K, Novel oral formulation of Paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004;109:1558-63
   PubMed Web of Science ®Google Scholar
• Deepak L, Bhatt MD, Keith AA, et al.; for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• Gori AM, Marcucci R, Migliorini A, Incidence and clinical impact of dual non responsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734-9
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study. Society for Cardiovascular Angiography and Interventions (SCAI) 2009 Scientific Sessions
   Google Scholar
• Finn AV, Kolodgie FD, Harnek J, Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Kolodgie F, Virmani R. Temporal course of neointimal formation after drug-eluting stent placement: I our understanding of restenosis changing? J Am Coll Cardiol Intv 2009;2:300-2
   Web of Science ®Google Scholar
• Guagliumi G, Sirbu V. Optical coherence tomography: high resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008;72(2):237-47
   PubMed Web of Science ®Google Scholar
• Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and sirolimus-eluting stent (Diabetes) trial. J Am Coll Cardiol 2006;47(11):2172-9
   PubMed Web of Science ®Google Scholar
• Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents a cause for concern. Circulation 2007;115:1440-55
   PubMed Web of Science ®Google Scholar
• Grube E, Dawkins K, Guagliumi G, TAXUS VI final 5-year results: a multicentre, randomized trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention 2009;4(5):572-7
   PubMedGoogle Scholar
• Holmes DR Jr, Teirstein PS, Satler L, 3-Year follow-up of the SISR (sirolimus-eluting stents versus vascular brachytherapy for in-stent restenosis) Trial. J Am Coll Cardiol Interv 2008;1:439-48
   Web of Science ®Google Scholar
• Rodríguez AE, Waksman R. Sirolimus-eluting stents or vascular brachytherapy for in-stent restenosis after 3-year follow-up of the SISR (Sirolimus-eluting stent versus vascular brachytherapy for in-stent restenosis) Trial: a call for caution? J Am Coll Cardiol Intv 2009;2:75-6
   Web of Science ®Google Scholar
• Van Der Hoeven BL, Liem SS, Dijkstra J, Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! Intervention study. J Am Coll Cardiol Intv 2008;1(2):192-201
   Web of Science ®Google Scholar
• Cook S, Wenaweser P, Togni M, Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-34
   PubMed Web of Science ®Google Scholar
• Windecker S, Serruys PW, Wandel S, Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): a randomized non-inferiority trial. Lancet 2008;372(9644):1163-73
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Onuma Y, A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple Imaging methods. Lancet 2009;373(9667):897-910
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ong ATL, Piej JJ, A randomized comparison of a durable polymer everolimus-eluting coronary stent with a bare metal coronary stent. EuroIntervention 2006;2:286-94
   PubMedGoogle Scholar
• Fajadet J, Wins W, Laarman GJ, Randomized, double blind, multicenter study of the Endeavor zotarolimus phosporilcoline encapsulated stent for the treatment of native coronary lesions: Clinical and Angiographic Results from the ENDEAVOR II Trial. Minerva Cardioangiol 2007;55:1-18
   PubMedGoogle Scholar
• Tardiff JC, Gregoire J, Lallier PL. Prevention of restenosis with antioxidants: mechanism and implications. Am J Cardiovasc Drugs 2002;2(5):323-34
   PubMedGoogle Scholar
• Serruys PW, Pim de Feyter, Macaya C, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3215-22
   PubMed Web of Science ®Google Scholar
• Douglas JS, Holmes DRJr, Kereiakes DJ. Coronary stent restenosis in patient treated with cilostazol. Cilostazol for restenosis trial (CREST) Investigators. Circulation 2005;112(18):2826-32
   PubMed Web of Science ®Google Scholar
• Jeong YH, Lee SW, Choi BR, Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTENCE (Adjuntive Cilostazol Versus High Maintenance Dose Clopidogrel in Patient With Clopidogrel Resistence) randomized study. J Am Coll Cardiol 2009;53(13):1101-9
   PubMed Web of Science ®Google Scholar
• Vezina C, Kudelski A, Sehgal SN. Rapamicyn (AY-22,989), a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975;28:721-6
   PubMed Web of Science ®Google Scholar
• Ge J, Shen C, Liang C, Elevated matrix metalloproteinase expression after stent implatantation is associated with restenosis. Int J Cardiol 2006;112(1):85-90
   PubMed Web of Science ®Google Scholar
• Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5
   PubMed Web of Science ®Google Scholar
• Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22(11):1769-76
   PubMed Web of Science ®Google Scholar
• Jones GT, Kay IP, Chu JW, Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 2006;26(7):e121-5
   PubMed Web of Science ®Google Scholar
• Brito FS Jr, Rosa WC, Arruda JA, Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia. Catheter Cardiovasc Interv 2005;64(4):413-18
   PubMed Web of Science ®Google Scholar
• Rodríguez A, Maree A, Tarragona S, Percutaneous coronary interventions with oral sirolimus plus bare metal stents has comparable efficacy and safety to treatment with drug eluting stents, but with significant cost saving: long term follow up results from the randomized, controlled ORAR III Study. EuroIntervention 2009;5:255-64
   PubMed Web of Science ®Google Scholar
• Beohar N, Davidson CJ, Kip KE, Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297(18):1992-2000
   PubMed Web of Science ®Google Scholar
• Win HK, Caldera AE, Maresh K, et al.; for the EVENT registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297(18):2001-9
   PubMed Web of Science ®Google Scholar
• Jhon M, Acampado E, Oral Everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-84
   PubMed Web of Science ®Google Scholar
• Dong-Woon K, Jin-Sook K, Young-Gyu K, Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004;109:1558-63
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ruygrok P, Neuzner J, A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286-94
   PubMedGoogle Scholar
• Westedt U, Kalinowski M, Wittmar M, Poly(vinyl alcohol)-graft-poly (lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. J Control Release 2007;119(1):41-51
   PubMed Web of Science ®Google Scholar
• Elford HL, Cardounel AJ. 20080050414; 2008
   Google Scholar
• Rodríguez AE, Maree AO, Mieres J, Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J 2007;28(17):2118-25
   PubMed Web of Science ®Google Scholar
• Morice MC, Colombo A, Meier B, Sirolimus vs paclitaxel eluting stents in de novo coronary artery lesions: the REALITY Trial A Randomized Controlled trial. JAMA 2006;295:895-904
   PubMed Web of Science ®Google Scholar
• Serruys PW, Daemen J, Morice MC, Three years follow up of the ARTS-II-sirolimus eluting stents for the treatment of patients withmultivessel coronary artery disease. EuroIntervention 2008;3:450-9
   PubMedGoogle Scholar
• Iakovou I, Schmidt T, Bonizzoni E, Incidence, predictors and outcome of thrombosis after successful implantation of drug eluting stents. JAMA 2005;293:2126-30
   PubMed Web of Science ®Google Scholar
• Rodríguez AE, Fernandez-Pereira C. Systemic immunosuppressive therapy with oral sirolimus after bare metal stent implantation: the missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. Rec Patents Cardiovasc Drug Discov 2008;3(3):201-8
   PubMedGoogle Scholar
• The BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007;49:1600-6
   PubMed Web of Science ®Google Scholar
• Daemen J, Ong AT, Stefanini GG, Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 2006;98(7):895-901
   PubMed Web of Science ®Google Scholar
• Machecourt J, Danchin N, Lablanche JM, Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007;50:501-8
   PubMed Web of Science ®Google Scholar
• Takagi T, Okura H, Kobayashi Y, A prospective, multicenter, randomized Trial to assess efficacy of pioglitazone of in stent neointimal suppression in type 2 diabetics. J Am Coll Cardiol Intv 2009;2:524-31
   Web of Science ®Google Scholar
• Yang J. WO080085293; 2008
   Google Scholar
• Kholodgi FD, John M, Khurana C, Sustained reduction of in stent neointimal growth with the use of the novel systemic nanoparticle of paclitaxel. Circulation 2002;106:1195-8
   PubMed Web of Science ®Google Scholar
• Scheller B, Hehrlein C, Bocksch W, Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355(20):2113-24
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT, Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91
   PubMed Web of Science ®Google Scholar
• James SK, Stenestrand U, Lindbäck J, Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009;360:1933-45
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov; 2009
   Google Scholar
• The BARI 2 Study Group. Randomized Trial of Therapies From Type 2 Diabetes and Coronary Artery Disease. N Engl J Med 2009;360:2503-15
   PubMed Web of Science ®Google Scholar